CLINICAL TRIALS PROFILE FOR SULFASALAZINE
✉ Email this page to a colleague
All Clinical Trials for SULFASALAZINE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00001422 ↗ | A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis | Completed | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 2 | 1995-06-01 | This is a placebo controlled study evaluating the role of fludarabine (a nucleoside analog targeting both resting and proliferating lymphocytes) in the treatment of moderate to severe psoriotic arthritis. Patients should have failed at least one disease modifying antirheumatic drug. |
| NCT00001677 ↗ | Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy | Completed | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 2 | 1998-06-01 | The safety profile and efficacy of combination therapy will be evaluated using methotrexate (MTX) and the nucleoside analog fludarabine in 40 patients with severe refractory rheumatoid arthritis. The patients enrolled will be those who have experienced inadequate disease control with MTX alone or in combination with other immunosuppressive drugs such as sulfasalazine (SSZ), cyclosporin A (CsA), or hydroxychloroquine (HCQ). In this randomized, double-blind, placebo controlled trial, patients will be maintained on oral MTX at 17.5 mg/week to which either placebo or subcutaneous fludarabine at 30 mg/m(2) daily for three consecutive days per month will be added for four months. The fludarabine (or placebo) treatment period will be followed by two months of follow-up, at which time patients will be evaluated for response. Patients will be monitored for adverse effects/tolerability, disease activity, and changes in synovial volume as measured by magnetic resonance imaging (MRI). Additionally synovial biopsies will be obtained before and after treatment for investigation of infiltrating cell numbers and phenotypes, cytokine profiles, Th1 versus Th2 responses, and angiogenesis. |
| NCT00004288 ↗ | Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis | Completed | University of Rochester | Phase 2 | 1996-05-01 | OBJECTIVES: I. Assess the safety and efficacy of olsalazine, a dimer of 5-aminosalicylic acid, in men with ankylosing spondylitis unresponsive to nonsteroidal anti-inflammatory drugs and physiotherapy. |
| NCT00004288 ↗ | Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis | Completed | National Center for Research Resources (NCRR) | Phase 2 | 1996-05-01 | OBJECTIVES: I. Assess the safety and efficacy of olsalazine, a dimer of 5-aminosalicylic acid, in men with ankylosing spondylitis unresponsive to nonsteroidal anti-inflammatory drugs and physiotherapy. |
| NCT00004810 ↗ | Phase II Placebo-Controlled Study of 4-Aminosalicylic Acid for Ulcerative Colitis | Completed | University of Vermont | Phase 2 | 1996-06-01 | OBJECTIVES: I. Assess the safety and efficacy of 4-aminosalicylic acid in patients with mildly to moderately severe ulcerative colitis. |
| NCT00004810 ↗ | Phase II Placebo-Controlled Study of 4-Aminosalicylic Acid for Ulcerative Colitis | Completed | National Center for Research Resources (NCRR) | Phase 2 | 1996-06-01 | OBJECTIVES: I. Assess the safety and efficacy of 4-aminosalicylic acid in patients with mildly to moderately severe ulcerative colitis. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SULFASALAZINE
Condition Name
Clinical Trial Locations for SULFASALAZINE
Trials by Country
Clinical Trial Progress for SULFASALAZINE
Clinical Trial Phase
Clinical Trial Sponsors for SULFASALAZINE
Sponsor Name
